Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from t

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PL

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the an

FORTIFY, a Phase 1b indication expansion trial of PLN-101095,  experiencing strong enrollment Appoin

Appointments bring global oncology drug development experience  and deepen Board's operational and r

Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 T

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095  enrolling patients with I

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral present

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLR

Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) t

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median

Shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) have been assigned an average r

Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Fr

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the disco

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: P

Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and

Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweigh

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.38) per share which beat the anal

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory

In February, we welcomed 17 new analysts to Seeking Alpha. This article showcases their stock picks

Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PL

Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) was the recipient of a large increase in

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its

One complete response and three partial responses observed  in heavily pretreated ICI-secondary refr

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after th

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the compan

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big

  During the session on Thursday, 461 stocks hit new 52-week lows.

  Friday's session saw 169 companies set new 52-week lows.

Gainers Hongli Group Inc. (NASDAQ: HLP) gained 317.8% to $17.55 in pre-market trading. Hongli Gro

Gainers

Gainers

Upgrades

Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on

Gainers Pliant Therapeutics, Inc. (NASDAQ: PLRX) jumped 112.6% to $18.88 after the company said